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Introduction
Platelet accumulation and coagulation system activation are two key 
mechanisms required to stop bleeding (1–3). At the site of vascular 
injury, subendothelial matrix exposure initiates platelet adhesion, 
activation, and aggregation, which constitute the first wave of hemo-
stasis (or primary hemostasis). Exposure of tissue factor and proco-
agulant cell membranes activates the coagulation cascade, a series 
of enzymatic reactions leading to the formation of a fibrin clot (i.e., 
the second wave of hemostasis or secondary hemostasis). However, 
if platelets and coagulation are inappropriately activated, thrombosis 
and vessel occlusion may occur, which can lead to life-threatening 
conditions, including myocardial infarction and stroke, the major 
causes of mortality and morbidity worldwide (4). A better under-
standing of the mechanisms underlying thrombosis is crucial for 
treatment and prevention of thrombotic and hemorrhagic disorders.
Fibronectin (Fn), a dimer of 250-kDa subunits, is a key com-
ponent of the extracellular matrix and is required for embryonic 
development (5). Fn exists as plasma Fn (pFn) and cellular Fn. 
Unlike cellular Fn, which is produced by various cell types and 
deposits locally, pFn is synthesized in the liver and secreted into 
the blood, in which it circulates at a relatively high concentra-
tion (230–650 μg/ml) (6, 7). Both subunits of the Fn dimer con-
tain N terminus fibrin and collagen-binding sites as well as a 
C terminus arginine-glycine-aspartic acid (RGD) motif (i.e., the 
integrin-binding site). The N terminus collagen-binding site may 
play a role in mediating the incorporation of pFn into the vessel 
wall (8, 9). Collagen, a major subendothelial matrix protein, can 
be easily exposed to blood components after the denudation of 
endothelial cells following injury. However, the efficiency of this 
pFn-collagen interaction under flow conditions and whether this 
process contributes to hemostasis in vivo have not been elucidat-
ed. The N terminus of pFn can also cross-link to the C terminus 
of the fibrin α chain by factor XIIIa (FXIIIa), thus enabling pFn 
incorporation into fibrin clots (10). Notably, Fn, fibrinogen (Fg), 
components of the coagulation cascade, and the type I Fn module 
(present 12 times in Fn and as single modules in several cascade 
components) arose together in evolution and are all vertebrate 
inventions (11–13). Despite these intriguing observations, there is 
no evidence supporting a significant contribution of pFn to blood 
coagulation. The C terminus RGD motif on pFn is also relevant 
to hemostasis; through binding to integrins on endothelial cells, 
fibroblasts, and adherent platelets, a pFn matrix can assemble on 
these cell surfaces (14–16), which may contribute to platelet accu-
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controls the diameter of fibrin fibers, increases the mechani-
cal strength of the clot, and is actively involved in thrombosis. 
Through switching its function in platelet aggregation, based on 
the presence or absence of fibrin (not VWF), pFn provides a self-
limiting mechanism that prevents excessive platelet accumula-
tion and vessel occlusion. These findings provide a solution for 
the controversy surrounding the function of pFn in hemostasis 
and establish pFn as a unique regulatory factor in thrombosis.
Results
pFn is a vital hemostatic factor in Fg deficiency. Conditional knock-
out of pFn in mice results in depletion of plasma pFn (>98%) in 
Cre+ mice but not in Cre– controls (21, 25). Although a previous 
study with pFn single-deficient mice did not report significantly 
impaired hemostasis with a tail bleeding assay (21), we encoun-
tered markedly increased mortality due to severe bleeding in 
FG–/– Vwf–/– pFn–/– (TKO) mice (18 of 78, 23.1%) compared with 
that in their pFn+/+ FG–/– Vwf–/– littermates (6 of 66, 9.1%, P < 0.05) 
(Figure 1A and Table 1). Severe bleeding in pFn-depleted mice was 
observed several days after the pFn levels decreased, and most of 
the deaths occurred within 1 to 2 weeks of pFn depletion. Autopsy 
revealed severe subcutaneous and/or abdominal bleeding (Figure 
1A). The tail bleeding time in TKO mice mice that survived the 
first month following pFn depletion was significantly longer than 
that in their pFn+/+ FG–/– Vwf–/– littermates (Figure 1B). In half of the 
TKO mice (4 of 8), the bleeding did not stop spontaneously within 
the observed time, whereas most of the pFn+/+ FG–/– Vwf–/– mice 
(10 of 11) achieved hemostasis spontaneously.
To determine whether the increased mortality after pFn deple-
tion was due to an associated deficiency in Fg or VWF, we estab-
lished 2 new strains of doubly deficient mice, FG–/– pFn–/– and 
Vwf–/– pFn–/– mice. There was no significant difference in blood 
cell counts or in the expression of major platelet surface adhe-
sion molecules between pFn–/– and pFn+/+ Cre– littermates (Supple-
mental Table 1 and Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI74630DS1). The 
mortality rate following pFn depletion was significantly higher in 
FG–/– pFn–/– mice than in pFn+/+ FG–/– littermates (22.6% and 5.5%, 
respectively; P < 0.05) (Table 1). Similar to the TKO mice, death 
was due to severe subcutaneous and/or abdominal bleeding. 
We found that tail bleeding time was also markedly prolonged in 
FG–/– pFn–/– mice compared with that in pFn+/+ FG–/– littermates 
(Figure 1C), and half of the FG–/– pFn–/– mice did not stop bleed-
ing spontaneously (7 of 14), while only 2 FG–/– mice bled beyond 
the observed time (2 of 11). Although there was no significant 
difference in the mortality rates of Vwf–/– pFn–/– and pFn+/+ Vwf–/– 
littermates (Table 1), the tail bleeding time in Vwf–/– pFn–/– mice was 
significantly longer (Supplemental Figure 2). These results suggest 
that Fg, but not VWF, deficiency, was associated with the increased 
mortality after pFn depletion and that pFn is an essential hemo-
static factor in Fg deficiency, and pFn contributes to hemostasis 
in VWF deficiency.
We next examined whether transfusion of purified pFn could 
ameliorate the severe bleeding phenotype in FG–/– pFn–/– mice. As 
a considerable amount of Fg contamination was found in com-
mercial pFn and pFn purified from WT mice (Supplemental Fig-
ure 3B), pFn used in this study was purified from blood collected 
mulation and hemostatic plug formation. Moreover, as we dem-
onstrated previously, circulating pFn can be taken up by platelets 
via β3 integrin (17), particularly in the absence of Fg competition 
(17, 18). Although the role of this internalized pFn has not been well 
studied, it is conceivable that increased platelet pFn content may 
be a compensatory mechanism to support hemostasis in individu-
als with afibrinogenemia. The abundance of pFn in the plasma and 
within platelets, as well as its interaction with components of the 
subendothelial matrix and coagulation cascade, has led to a long-
held suspicion that pFn may play a role in hemostasis (3, 18–20), 
but there has been no direct in vivo evidence.
Germ line Fn deficiency is embrionic lethal in mice (5). Our 
earlier study with pFn conditional knockout mice using intravital 
microscopy revealed that pFn promotes thrombus growth and sta-
bility in injured arterioles (19, 21). We also reported that platelet 
aggregation and thrombus formation persist in mice lacking Fg, 
von Willebrand factor (VWF), or both (18, 22); Fg and VWF have 
been considered to be the two key molecules mediating platelet 
adhesion and aggregation. In the absence of Fg or both Fg and 
VWF, platelet pFn content is markedly increased in mice and 
human patients (18, 23, 24). It was therefore speculated that pFn 
may be the factor that mediates this Fg/VWF-independent throm-
bus formation. Paradoxically, we observed that depletion of pFn 
in mice doubly deficient in Fg and VWF (FG–/– Vwf–/–) enhances, 
rather than abolishes, platelet aggregation and thrombus forma-
tion (25). These findings led us to hypothesize that pFn has con-
text-specific functions (i.e., a functional switch based on the pres-
ence of Fg and/or VWF) in the hemostatic system such that pFn 
can both support hemostatic plug formation and inhibit thrombus 
buildup. However, the mechanisms that mediate the switch of pFn 
functions are unknown.
To investigate the role of pFn in hemostasis and the mecha-
nism that controls the context-specific functions of pFn (i.e., 
whether Fg or VWF dictated the pFn functional switch), using 
a conditional transgenic mouse (Fnfl/fl Mx-Cre mice, referred 
to herein as pFn–/– mice) (21), we established Fg and pFn 
double-deficient (FG–/– pFn–/–) and VWF and pFn double-deficient 
(Vwf–/– pFn–/–) mouse strains. We found that pFn is a vital survival 
factor for hemostasis in Fg deficiency and supports hemostasis 
in VWF deficiency. We showed that pFn deposition precedes the 
classical first wave of hemostasis (i.e., platelet accumulation) in 
both WT and these deficient mice. pFn integrates with fibrin, 
Table 1. High mortality rate in mice with combined deficiencies of 
both Fg and pFn
Total no. of mice No. of dead mice Mortality (%)
pFn+/+ FG–/– 55 3 5.5%
FG–/– pFn–/– 53 12 22.6%A
pFn+/+ Vwf–/– 57 1 1.8%
Vwf–/– pFn–/– 51 0 0%
pFn+/+ FG–/– Vwf–/– 66 6 9.1%
TKO 78 18 23.1%A
Mortality rate was calculated 1 month after polyinonic-polycytidylic acid 
injection. AP < 0.05.
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mice was significantly prolonged compared with that in pFn+/+ lit-
termates, and over half of the mice did not stop bleeding sponta-
neously (5 of 9) (Figure 1E). Likewise, recombinant hirudin also 
significantly prolonged the tail bleeding time in pFn–/– mice but not 
in pFn+/+ mice (Figure 1E). We next examined whether transfusion 
of pFn could prevent excessive bleeding after high-dose antico-
agulant treatment. WT mice were given a high dose of heparin 
(200 U, i.p.) and then treated with either i.v. PBS or pFn (1.5 mg/ml, 
200 μl). After treatment with PBS, none of the mice (8 of 8) had 
stopped tail bleeding spontaneously at 20 minutes. However, the 
majority of the mice (5 of 8) treated with pFn achieved hemostasis 
(arrest of bleeding) within 20 minutes (17.27 minutes, 95% confi-
dence interval [14.79 minutes, 19.75 minutes], P < 0.05) (Figure 
1F). These findings suggest that pFn is important for hemostasis 
in individuals who are unable to generate fibrin normally, such as 
patients receiving anticoagulant therapy.
from FG–/– mice (Supplemental Figure 3, A and B). Compared with 
transfusion of 200 μl PBS or BSA solution, transfusion of the same 
volume of pFn solution (1.5 mg/ml, 200 μl) significantly short-
ened the tail bleeding time in FG–/– pFn–/– mice (Figure 1D). All of 
the mice transfused with pFn achieved hemostasis spontaneously 
within 20 minutes, whereas, even after 30 minutes, bleeding 
failed to stop in 3 of 6 mice transfused with PBS and in 2 of 7 mice 
transfused with BSA. This is strong evidence that pFn supports 
hemostasis in vivo and is a key survival factor in Fg deficiency.
pFn is important for hemostasis following treatment with antico-
agulants. Anticoagulants, such as heparin and hirudin, have been 
widely used for prevention and treatment of thrombosis by inhib-
iting thrombin function and conversion of Fg to fibrin. In patients 
on anticoagulant therapy, major bleeding complications occur 
and are associated with increased mortality. Here, we found that 
after heparin treatment (20 U, i.p.) the tail bleeding time in pFn–/– 
Figure 1. pFn is a key hemostatic factor in deficiencies of Fg and blood coagulation. (A) Representative images of abdominal and subcutaneous bleeding 
in TKO mice. Red arrows show the bleeding site. (B) Tail bleeding time in WT, FG–/– Vwf–/–, and TKO mice. (C) Tail bleeding time in FG–/– and FG–/– pFn–/– 
mice. (D) Tail bleeding time in FG–/– pFn–/– mice transfused with 200 μl PBS, 1.5 mg/ml purified pFn, or BSA. (E) Tail bleeding time in pFn–/– mice and their 
WT (pFn+/+) littermates treated with i.p. injection of PBS, 20 U heparin, or 0.5 mg/kg recombinant hirudin (r-hirudin). Tail bleeding assay was performed 
30 minutes after the injection. (F) Tail bleeding time in WT mice given high-dose heparin (200 U) and then transfused with PBS or pFn. For all tail bleeding 
assays, 2 mm of the tip of the tail was severed. Bleeding time assay was terminated at 20 or 30 minutes, as indicated, and mice that bled beyond this end 
point were counted as 20 or 30 minutes, respectively. Data are presented as mean ± SEM. Individual symbols represent individual mice.
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deposition of fluorescently labeled pFn at sites of vessel injury in 
FG–/– Vwf–/– mice occurred prior to significant platelet accumula-
tion (Figure 2E and Supplemental Video 1). Deposition of pFn was 
also primarily found at the base of the growing hemostatic plug. 
While platelet accumulation reached its maximum and began to 
dissociate at approximately 1.5 minutes, pFn continued to deposit 
and reached a plateau at approximately 3.5 minutes. The fluores-
cence intensity of pFn at the site of injury did not decrease as the 
platelets dissociated from the hemostatic plug (Figure 2F), and 
the amount of pFn deposition in FG–/– Vwf–/– mice was similar to 
that in WT mice during the 4-minute observation (P > 0.05, Sup-
plemental Figure 4, A and B). These observations suggest that, in 
the absence of Fg and VWF, pFn can also deposit on the vessel 
wall prior to significant platelet accumulation but does not sig-
nificantly incorporate into the growing platelet plug as compared 
with the WT mice.
Using confocal microscopy, marked pFn deposition was also 
observed in the FeCl3 injury mesenteric thrombosis model in 
FG–/– Vwf–/– mice (Figure 2G and Supplemental Video 2). Platelets 
accumulated on top of the pFn layer, indicating that pFn deposition 
occurred prior to platelet accumulation. We confirmed that early pFn 
deposition occurred in injured cremaster and mesenteric vessels in 
FG–/– mice (Figure 3, A and B) and β3 integrin–deficient (Itgβ3–/–) mice 
(Figure 3, C and D, and Supplemental Videos 1 and 2). Furthermore, 
after antibody-induced depletion of platelets in WT mice (28), simi-
lar deposition of pFn was observed on the injured vessel wall (Sup-
plemental Figure 4C). pFn fluorescence was clearly visible at the site 
of injury 60 minutes after laser injury, even after the platelet throm-
bus dissociated from the vessel wall (Figure 3E), suggesting that pFn 
was incorporated into the subendothelial matrix.
After heparin treatment, minimal platelet accumulation 
was observed 5 minutes after injury, yet pFn deposition on the 
injured vessel wall remained similar to that in untreated WT 
controls (Figure 3F). Considering that most pFn+/+ (but not pFn–/–) 
mice treated with the same dose of heparin achieved hemosta-
sis within 5 minutes in the tail bleeding assay (Figure 1E), these 
data suggest a major contribution of pFn in controlling bleeding 
following anticoagulant treatment.
Collagen is a major subendothelial matrix protein and can bind 
to the N terminus of pFn (8), but this process has not been well 
studied under flow conditions. Here, we found rapid deposition of 
pFn on collagen within 40 seconds when purified pFn was perfused 
over a collagen-coated surface under arterial shear rate, while no 
deposition of BSA was observed (Supplemental Figure 4D and Sup-
plemental Video 3). This observation demonstrated that collagen 
could mediate the rapid and efficient deposition of pFn.
pFn deposition is a hemostatic event preceding the classical first 
wave of hemostasis. It is widely accepted that platelet accumula-
tion at the site of injury comprises the initial wave of hemostasis. 
Although we observed severe bleeding in the FG–/– pFn–/– mice, 
we previously and paradoxically found that depletion of pFn in 
FG–/– Vwf–/– mice enhances thrombus formation and stability (25). 
Thus, the life-threatening hemorrhage that we observed was 
likely not caused by a defect in platelet accumulation. To begin to 
explore the unique contributions of pFn to hemostasis, we exam-
ined the distribution of pFn at the site of vascular injury.
Using a laser injury cremaster arterial intravital microscopy 
model (25–27), we observed rapid deposition of fluorescently 
labeled pFn at sites of vessel injury in WT mice, whereas no BSA 
deposition was observed (Figure 2, A and B, and Supplemental 
Video 1). Interestingly, pFn deposited even prior to significant 
platelet accumulation (i.e., the classical first wave of hemosta-
sis) (Figure 2A and Supplemental Video 1). Deposition of pFn 
was primarily found at the base of the growing hemostatic plug, 
which extended from the vessel wall into the bottom part of the 
hemostatic plugs adjacent to the vessel wall, colocalizing with 
approximately 45% (44.1% ± 3.4%) of the hemostatic plug (Figure 
2A). pFn fluorescence intensity at the site of injury reduced as the 
platelet thrombi dissociated (Figure 2C). Importantly, pFn fluores-
cence in the thrombi gradually decreased as the thrombi extended 
into the vessel lumen, such that pFn was almost undetectable on 
the apical surface of the thrombi (Figure 2A). These findings sug-
gest that in WT mice there is a gradient of pFn from the vessel wall 
(high pFn) to the apex of the thrombi (little or undetectable).
This process was further observed in WT mice under a laser 
scanning confocal microscope in a FeCl3 injury mesenteric throm-
bosis model (18, 25). To exclude the possibility that the early detec-
tion of pFn in the previous cremaster arterial model was caused by 
greater microscope sensitivity for Alexa Fluor 488, we switched 
the labeling of pFn and platelets to Alexa Fluor 647 and DyLight 
488, respectively. 3D reconstruction of the confocal images 
revealed that 5 minutes after FeCl3 injury, the entire luminal side 
of the injured vessel wall (artery and vein) had been covered with 
a layer of deposited pFn (Figure 2D and Supplemental Video 2). 
In both veins and arteries, platelets accumulated on top of the 
pFn layer, indicating that pFn deposition occurred prior to platelet 
accumulation. This observation was consistent in all 5 mice stud-
ied: platelet fluorescence was only detectable on the luminal side, 
on top of the pFn layer already deposited.
We then studied whether pFn deposition persists in the 
absence of Fg and VWF using the laser injury cremaster arte-
rial thrombosis model. As observed in the WT mice, the rapid 
Figure 2. pFn deposition is a hemostatic event preceding platelet accumulation. (A) pFn deposition and platelet accumulation in WT mice in the laser-
induced cremaster arterial thrombosis model. pFn deposition at the injury site was apparent 10 seconds after laser injury, prior to significant platelet 
accumulation. (B) No deposition of fluorescently labeled BSA was observed. (C) pFn deposition and platelet accumulation at the site of injury of WT mice 
in the cremaster arterial thrombosis model were measured by fluorescence intensity. The curves represent pFn or platelet mean fluorescent intensity, and 
the shaded regions represent SEM (n = 5 in each group). (D) 3D reconstruction of pFn deposition and initial platelet accumulation in mesenteric arteries and 
veins 5 minutes after FeCl3 injury in WT mice. The images shown are the longitudinal sections of the vessels, viewed from the inside of the lumen or from 
the outside the vessel wall. (E) pFn deposition and platelet accumulation in FG–/– Vwf–/– mice in the laser-induced cremaster arterial thrombosis model. (F) 
Measurement of fluorescent intensity of pFn deposition and platelet accumulation at the site of injury of FG–/– Vwf–/– mice in the cremaster arterial throm-
bosis model (n = 5 in each group). (G) 3D reconstruction of pFn deposition and initial platelet accumulation in mesenteric arteries and veins 5 minutes after 
FeCl3 injury in FG
–/– Vwf–/– mice. Scale bar: 10 μm (A, B, and E); 50 μm (D and G). All images shown are representative of at least 5 independent experiments.
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pFn reinforces the mechanical strength of fibrin clots. pFn can 
be covalently linked to fibrin by thrombin-activated FXIIIa and 
becomes incorporated into the fibrin clot (10). Using throm-
boelastography (TEG), fibrin clots formed in whole blood or 
platelet-poor plasma (PPP) from pFn+/+ mice were significantly 
stronger than those formed in whole blood or PPP from pFn–/– lit-
termates (Figure 4, A and B), although the rates of clot formation 
were similar in both groups (Supplemental Figure 5, A and B). The 
decrease in clot strength was not due to difference in Fg concen-
tration (Supplemental Figure 6). Reintroduction of pFn into pFn–/– 
whole blood ameliorated the defect in clot strength (Figure 4C). 
Compared with adding PBS or BSA controls, the reintroduction 
of pFn to a final concentration of 300 μg/ml raised the maximum 
amplitude (MA) in pFn–/– blood to about 60% (Figure 4C). These 
findings suggest that pFn supports hemostasis not only through 
deposition at the injured vessel wall but also by enhancing the 
strength of the fibrin network.
pFn controls the diameter of fibrin fibers. We then studied the 
formation of the pFn-fibrin network in vitro. Fluorescently labeled 
murine pFn, which was purified from FG–/– mice, was actively 
recruited to the fibrin network formed in mouse PPP, resulting in 
thicker fibrin fibers compared with those in BSA-treated PPP (Figure 
4D and Supplemental Figure 5C). Using scanning electron micros-
copy, we found that addition of 330 μg/ml pFn to pFn–/– mouse PPP 
significantly increased fibrin fiber diameter compared with addi-
tion of PBS alone (113.6 ± 2.8 nm and 69.4 ± 0.6 nm, respectively, 
P < 0.01) (Figure 4, E and F). Consistent with this, the diameter of 
fibrin fibers formed in PPP from pFn+/+ mice was significantly larger 
than that formed in PPP from pFn–/– mice (Figure 4, H and I).
To examine whether pFn also controls the diameter of human 
fibrin fibers, a gelatin column was used to remove endogenous pFn 
from human PPP. Human pFn, BSA, or PBS were then added to 
the pFn-depleted PPP. We found that, as in the mouse PPP, pFn 
was actively recruited into the fibrin network (Figure 5A). After 
addition of 330 μg/ml human pFn, the diameter of fibrin fibers 
increased from 90.7 ± 2.8 nm to 147.2 ± 10.0 nm (P < 0.01, Figure 5, 
B and C). Consistent with the increased fiber diameter, fiber den-
sity decreased in the presence of pFn in both mouse and human 
plasma (Figure 4, G and J, and Figure 5D). These findings suggest 
that pFn modulates fibrin clot structure by enhancing the lateral 
aggregation of the fibrin protofibrils.
Non-fibrin-linked soluble pFn decreases platelet aggregation and 
thrombosis. The role of pFn in platelet aggregation remains con-
troversial (29–32). Our earlier study showed that fibrin is required 
for the retention of pFn on the platelet surface (rendering pFn 
insoluble) (23). In the absence of Fg, platelet pFn content increases 
Figure 3. pFn deposition on the injured vessel wall is independent of Fg and β3 integrin and persists after heparin treatment. (A) pFn deposition and 
platelet accumulation in FG–/– mice in the laser-induced cremaster arterial thrombosis model. Images were taken at 1 minute after injury. (B) 3D recon-
struction of pFn deposition and initial platelet accumulation in mesenteric arteries and veins 5 minutes after FeCl3 injury in FG
–/– mice. (C) pFn deposition 
and platelet accumulation in Itgβ3–/– mice in the laser-induced cremaster arterial thrombosis model. Images were taken at 1 minute after injury. (D) 3D 
reconstruction of pFn deposition and initial platelet accumulation in a mesenteric artery 5 minutes after FeCl3 injury in a Itgβ3
–/– mouse. (E) Fluorescently 
labeled pFn is detectable at the injury site 60 minutes after laser injury in WT mice. (F) 3D reconstruction of pFn deposition and initial platelet accumula-
tion in mesenteric arteries and veins 5 minutes after FeCl3 injury in WT mice treated with heparin. Scale bar: 10 μm (A, C, and E); 50 μm (B, D, and F). All 
images shown are representative of at least 5 independent experiments.
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3- to 5-fold (17, 18). In our current study, we first found that in 
FG–/– mice this pool of pFn decreased aggregation of gel-filtered 
platelets (Figure 6A). In Vwf–/– mice, in which Fg was present, pFn 
enhanced aggregation of gel-filtered platelets induced by throm-
bin (which converts the platelet-released Fg to fibrin). However, 
when thrombin receptor-activating peptide (TRAP; AYPGKF, a 
potent PAR4-activating peptide) and collagen (neither of which 
convert Fg to fibrin) were used as an agonist in the same prepara-
tion of gel-filtered platelets, pFn attenuated platelet aggregation 
(Figure 6, B and C). ADP-induced platelet aggregation in Vwf–/– 
Figure 4. pFn enhances the mechanical strength of the fibrin clot and controls the diameter of fibrin fibers in mice. (A–C) Representative TEG tracings 
and MA measured by TEG in (A) whole blood and (B) PPP. (C) Adding back purified pFn partially rescued the MA of pFn–/– blood. n = 5 in each group. (D) 
Confocal images of mouse pFn-fibrin network formed in vitro (z projection of 11 individual slides taken at 1-μm interval across the 10-μm thickness of 
the clot). Mouse pFn or BSA was added into pFn–/– mouse PPP to a final concentration of 330 μg/ml. (E) Scanning electron microscopy analysis of mouse 
pFn-fibrin network formed in vitro. The same volume of PBS and mouse pFn was added into pFn–/– mouse PPP (final concentration 330 μg/ml). (H) 
Scanning electron microscopy analysis of pFn+/+ and pFn–/– mouse pFn-fibrin network formed in vitro. pFn-fibrin network formation was initiated with 
0.5 U/ml murine thrombin and 30 mM CaCl2. (F and I) Average diameter of pFn-fibrin fibers formed in vitro. (G and J) Average density of pFn-fibrin fibers 
formed in vitro. Average diameter and density were calculated by counting the fibers crossed by 2 diagonal lines in a 1-μm2 square. n = 9 in each group. 
Scale bar: 20 μm (D); 1 μm (E and H).
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in pFn+/+ littermate controls (Figure 6E). This demon-
strated that the pFn contributes to platelet aggrega-
tion and suggested that fibrin plays a critical role in 
switching pFn from an inhibitory to a supportive role 
in platelet aggregation.
We next studied the role of pFn in thrombosis 
in FG–/– mice. Consistent with our previous obser-
vation in TKO mice (25), depletion of pFn in FG–/– 
mice enhanced thrombus formation in the ex vivo 
perfusion chamber model (Figure 6, F and G) and 
in vivo in the laser injury cremaster arterial throm-
bosis model (Figure 6, H and I). pFn therefore 
inhibits thrombus formation in mice lacking Fg 
(i.e., absence of Fg/fibrin).
Discussion
pFn was discovered as a protein that copurifies with 
Fg. It circulates in plasma in abundance and possess-
es the potential to assemble into fibrils that associate 
with various cell types, including platelets. Although 
it has long been suspected that pFn may play a role 
in the arrest of bleeding, its role in hemostasis has 
yet to be established. Here, we report an assessment 
of the role of pFn in hemostasis and thrombosis. We 
have demonstrated for the first time that, when fibrin 
formation is impaired, pFn is an essential survival 
factor; i.e., pFn is crucial for hemostasis in both FG–/– 
mice and in WT mice given anticoagulants. We found 
that pFn rapidly deposits onto the injured vessel wall, 
even prior to the classically recognized first wave of 
hemostasis, and remains at the site of injury. Through 
incorporation into the fibrin network, pFn controls the 
diameter of fibrin fibers and promotes the stability of 
the hemostatic plug. Interestingly, while pFn enhanc-
es platelet aggregation in the presence of fibrin, it 
inhibits platelet aggregation and thrombus formation 
in the absence of fibrin. This interaction with fibrin 
endows pFn with the capacity to switch from sup-
porting hemostasis to inhibiting thrombosis/vessel 
occlusion, based on the fibrin gradient, in which fibrin 
decreases as it gets farther from the injured endothe-
lium. These data establish pFn as an important hemo-
static factor in Fg and coagulation deficiencies and a 
unique self-limiting regulator in thrombosis.
Current theory holds that platelet accumulation 
constitutes the first wave of hemostasis, and hemo-
static events occurring before the platelet wave have 
not yet been adequately exposed. We have indicated 
that deposition of pFn at the site of injury is a key ini-
tial hemostatic process that occurs even earlier than 
the conventional first wave of hemostasis. These findings indi-
cate the existence of a previously unrecognized “Fn” or “protein” 
wave of hemostasis before the classical platelet wave. While stable 
platelet plug formation usually requires sufficient time for plate-
lets to adhere, activate, and aggregate, pFn and likely other plasma 
proteins accumulate on the subendothelial matrix immediately 
after injury. Importantly, the early deposited pFn can be noncova-
platelet-rich plasma (PRP) (which is unable to convert Fg to fibrin) 
was also enhanced after pFn depletion (Figure 6D). Therefore, in 
either FG–/– or FG+/+ blood, as long as there is no fibrin generation, 
pFn plays a purely inhibitory role in platelet aggregation. Con-
sistently, thrombin-induced gel-filtered platelet aggregation (in 
which platelet released Fg is converted to fibrin on platelet surface) 
was impaired in pFn–/– single-deficient mice as compared with that 
Figure 5. pFn controls the diameter of human fibrin fibers. (A) Confocal images of human 
pFn-fibrin network formed in vitro (z projection of 11 individual slides taken at 1-μm interval 
across the 10-μm thickness of the clot). Human pFn or BSA was added into pFn-depleted 
human PPP to a final concentration of 330 μg/ml. (B) Scanning electron microscopy analysis 
of human pFn-fibrin network formed in vitro. The same volume of PBS and human pFn was 
added into pFn-depleted human PPP (final concentration 330 μg/ml). (C) Average diameter 
of pFn-fibrin fibers formed in vitro. (D) Average density of pFn-fibrin fibers formed in vitro. 
Average diameter and density were calculated by counting the fibers crossed by 2 diagonal 
lines in a 1-μm2 square. n = 10 in each group. Scale bar: 20 μm (A); 1 μm (B).
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tion process that is crucial for the maintenance of vessel integrity. 
Together with FXIIIa and likely also protein disulfide isomerases 
(33), the initially deposited pFn may serve as a substrate to recruit 
other key proteins in hemostatic plug formation.
lently or covalently (via FXIIIa) linked to collagen (8), and the inte-
grins on subendothelial cells and on the adhered platelets are able 
to assemble pFn into a matrix (14–16). Therefore, the deposition of 
pFn at the site of injury is likely a well-orchestrated matrix forma-
Figure 6. Role of pFn in platelet aggregation and thrombus formation in the presence or absence of fibrin. (A) Thrombin-induced (0.2 U/ml) FG–/– 
pFn–/– and FG–/– gel-filtered platelet aggregation. (B) Thrombin-induced (0.2 U/ml) or TRAP-induced (500 μM) Vwf–/– pFn–/– and Vwf–/– gel-filtered 
platelet aggregation. (C) Collagen-induced (20 μg/ml) Vwf–/– pFn–/– and Vwf–/– gel-filtered platelet aggregation. (D) ADP-induced (20 μM) Vwf–/– pFn–/– 
and Vwf–/– platelet aggregation in PRP. (E)Thrombin-induced (0.2 U/ml) pFn+/+ and pFn–/– gel-filtered platelet aggregation. All representative tracings of 
platelet aggregation are shown from at least 3 independent experiments. (F) Thrombus formation in a collagen-coated perfusion chamber infused with 
blood from FG–/– pFn–/– mice and their pFn+/+ FG–/– littermates (shear rate = 1,800 s–1). Images were taken with a confocal microscopy after infusion for 
3 minutes. Grid in the image represents 10 μm. (G) Thrombus volume measured 3 minutes after infusion. n = 5 in each group. (H) Thrombus formation 
in FG–/– pFn–/– mice and their pFn+/+ FG–/– littermates observed in the laser-induced cremaster arterial thrombosis model. The curves represent pFn or 
platelet mean fluorescent intensity, and the shaded regions represent SEM. (I) The total area under the curve (AUC) was greater in FG–/– pFn–/– mice 
than in FG–/– mice. n = 5 in each group. Data are presented as mean ± SEM.
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and was therefore almost certainly contaminated with Fg or fibrin 
(Supplemental Figure 3B). Using pFn-deficient plasma and pFn 
purified from FG–/– mice, we were able to study, for the first time, 
the function of pFn in a natural plasma environment without Fg 
or fibrin contamination. We demonstrate that pFn increases the 
diameter of fibrin fibers and strengthens the fibrin clot, mainly by 
enhancing lateral aggregation and increasing fiber diameter. The 
mechanical and structural defects in pFn–/– fibrin clots are similar 
to those of a reported fibrin mutant deficient in lateral aggregation 
(39), suggesting that pFn enhances clot strength through enhanc-
ing lateral aggregation of fibrin protofibrils.
The role of pFn in platelet aggregation has been intensely 
debated for decades. While pFn has been shown to inhibit iono-
phore A23187- and collagen-induced platelet aggregation (29, 30), 
monoclonal antibodies against Fn inhibited platelet aggregation 
mediated by these agonists (31, 32). It has also been reported that 
pFn corrected a platelet aggregation defect in Ehlers-Danlos syn-
drome (a connective tissue disorder), although the mechanism 
is yet unclear (40). In our experiments, we found that thrombin-
induced aggregation of gel-filtered platelets was significantly stron-
ger in pFn+/+ platelets than in pFn–/– platelets (Figure 6E), although 
it is difficult to distinguish the difference in platelet aggregation 
between platelets from pFn–/– mice and pFn+/+ littermates induced 
either by ADP in PRP or TRAP and collagen in gel-filtered platelets. 
The inconsistency of the responses is likely due to different levels of 
fibrin generated during the sampling and in vitro experimental pro-
cesses. Using our unique FG–/– pFn–/– mouse (absence of fibrin) and 
Vwf–/– pFn–/– mouse (minimal incidental fibrin generation due to low 
FVIII activity) strains, we minimized the incidental fibrin genera-
tion and demonstrated that the effect of pFn on platelet aggregation 
and thrombosis is dependent on the presence or absence of fibrin.
In addition to free pFn in the blood plasma, during hemostatic 
plug formation, platelets may serve as a transporter of pFn. Accu-
mulating platelets carry and release their pFn content specifically 
at the injury site, which may markedly increase the local concen-
tration of pFn. The released pFn may be directly organized on the 
activated platelet surface into a matrix to support hemostasis. This 
portion of platelet-transported pFn is likely to be more important 
for the maintenance of hemostasis in Fg deficiency, because we 
previously found that the pFn content in platelets increased 3- to 
5-fold in both FG–/– mice and in patients with hypofibrinogenemia 
(18, 23, 24) as a result of increased uptake of pFn via the β3 integrin 
in the absence of Fg competition (17). The deposited pFn on the 
vessel wall may induce more platelet adhesion through a GPIb-
pFn interaction (34), which could lead to more pFn release from 
the platelets. Therefore, the platelet-transported pFn further mag-
nifies the initial “Fn” wave. Future investigation focusing on this 
“Fn” or “protein” wave of hemostasis will bring new insights into 
the initiation and maintenance of hemostasis.
In addition to local deposition and matrix formation at the site 
of injury, we demonstrated that pFn also contributes to hemosta-
sis through its incorporation into clots. The effect of pFn on the 
mechanical characteristics of fibrin clots has been controversial. 
Addition of pFn to a reconstituted Fg solution resulted in increased 
clot shear modulus and turbidity (35, 36); however, other studies 
proposed that pFn may block fibrin polymerization, leading to pro-
longed clotting time, decreased turbidity (37), and reduced elas-
ticity (38). This discrepancy is likely due to the methodology; all 
of these studies used reconstituted Fg solution rather than natural 
plasma, and the purity of reagents used was variable. The major 
challenge is to isolate pure pFn. pFn used in almost all of the previ-
ous studies was purified from healthy human subjects or WT mice 
Figure 7. pFn is a self-limiting factor for hemostasis and thrombosis. (A) Platelet accumulation and fibrin formation in WT mice in the laser-induced 
cremaster arterial thrombosis model. Fibrin forms at the bottom of the platelet thrombi, while at the top of the growing thrombi, fibrin is nearly undetect-
able. Scale bar: 10 μm. (B) Illustration of the self-limiting role of pFn for thrombosis after vascular injury. pFn deposited at the base of the hemostatic plug 
likely cross-links with fibrin to support platelet aggregation. The soluble pFn at the top of the thrombi is associated with platelets but not with fibrin. 
These pFn molecules play a solely inhibitory role, stabilizing the thrombus and suppressing excessive thrombus buildup, thus helping to form a restricted 
local hemostatic plug that maintains hemostasis without causing downstream ischemia. (C) Illustration of pFn promoting efficient hemostasis after 
severe vascular injury. After severe trauma to a vessel, a large amount of thrombin is generated from multiple sites of the injured vessel wall, so that even 
at the top of the growing thrombi, there is a sufficient amount of thrombin to initiate fibrin formation. Under this condition, pFn is continuously incorpo-
rated onto the top of the growing thrombus through fibrin. This fibrin cross-linked pFn promotes the formation of an occlusive thrombus and helps to stop 
blood loss efficiently after severe vascular injuries. Blue arrows indicate fibrin concentration change from high level (H, red) to low level (L, yellow) as the 
hemostatic plug extends from the vessel wall into to the vessel lumen.
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important to investigate the relationship of pFn level (e.g., low pFn 
level in patients with acute liver failure or severe cirrhosis) with 
bleeding complications associated with anticoagulant therapy. 
Furthermore, given that pFn is a major intrinsic component of 
many blood products, the role of pFn in blood transfusion, espe-
cially its potential hemostatic and antithrombotic benefit in trans-
fusion recipients, requires further study.
In summary, we have identified a new “Fn” or “protein” 
wave that occurs even earlier than the well-accepted first wave 
of hemostasis (i.e., platelet accumulation). We have also placed 
pFn as a component in the final steps of the coagulation cascade 
as a key factor that controls lateral aggregation of fibrin fibers. 
Moreover, we provided an explanation as to why the roles of pFn 
were previously controversial by demonstrating that it indeed 
has opposite effects (i.e., inhibitive and supportive) on platelet 
aggregation and identified that fibrin dictates the pFn functional 
switch. Further clinical investigation may lead to the develop-
ment of pFn transfusion as a unique therapeutic strategy to con-
trol bleeding and modulate thrombosis.
Methods
Further details are available in the Supplemental Methods.
Materials. DyLight 649 and DyLight 488 fluorescent labeled 
anti-GPIb antibodies and JON/A (antibody against mouse-activated 
GPIIbIIIa) were purchased from Emfret Analytics. Alexa Fluor 488 
and Alexa Fluor 647 protein labeling kits were purchased from Life 
Technologies Inc. Human Fg was purchased from Sigma-Aldrich. 
Recombinant hirudin was provided by Jawed Fareed at Loyola Uni-
versity, Chicago, Illinois, USA.
Mice. pFn–/– conditional knockout mice (Fnfl/fl Cre+) and control litter-
mates (Fnfl/fl Cre–) were originally generated in the laboratory of Reinhard 
Fässler (Max Planck Institute of Biochemistry, Martinsried, Germany) 
(21). Vwf–/– pFn–/– and FG–/– pFn–/– mice were generated by breeding female 
pFn conditional knockout (Fnfl/fl Cre+) mice with male Vwf–/– mice or male 
FG–/– mice, respectively. Genotype was detected by polymerase chain 
reaction and confirmed by Western blot. pFn depletion was induced by 
3 i.p. injections of 250 μg polyinonic-polycytidylic acid (Sigma-Aldrich) 
into Cre+ and Cre– littermates at 2-day intervals. pFn depletion in the plas-
ma and platelets was confirmed by Western blot.
Bleeding time. The bleeding time assay was modified from the pro-
cedure previously described (49). After anesthetizing 6- to 8-week-old 
mice with 2.5% tribromoethanol (0.015 ml/g) and maintaining them 
at 37°C with a heating pad, the tip of the tail (2 mm) was amputated 
with a sharp scalpel. In most Vwf–/– and Vwf–/– pFn–/– mice, tail bleed-
ing did not stop within 20 minutes of severing the tail tip. Therefore, 
instead of cutting the tail, one of the tail veins was punctured 4 cm 
from the tip of the tail. The injured tail was immediately placed into 
warm PBS maintained at 37°C, and the bleeding time was recorded 
from the time of injury until 10 seconds after bleeding had ceased. 
Bleeding time assay was terminated at 20 minutes, and mice that bled 
beyond this end point were counted as 20 minutes. For mice trans-
fused with 200 μl PBS, pFn, or BSA, we extended the end point of the 
tail bleeding assay to 30 minutes.
Preparation of plasma, platelets, and pFn. Mouse plasma and 
platelets were prepared as previously described (18, 22, 25, 50–52). 
For pFn-fibrin clot formation in vitro, blood was drawn from inferior 
vena cava with a 25-gauge needle and immediately mixed with 3.2% 
The 2 RGD motifs on the pFn dimer are in close proximity, 
rendering them unlikely to be easily accessed by integrins from 2 
platelets. When the N terminus of pFn cross-links with fibrin, the 
large pFn-fibrin complex may then be able to bind to platelets at 
RGD motifs on pFn and/or fibrin. The multiple integrin-binding 
sites enable the pFn-fibrin complex to bridge integrins on 2 or more 
platelets to support platelet aggregation. However, in the absence 
of fibrin (e.g., afibrinogenemia, anticoagulant therapy) or at the 
top of the thrombi, where fibrin is undetectable (Figure 7A), pFn 
binds to platelet surface integrins and prevents their interaction 
with other more potent ligands, such as Fg and other prothrom-
botic ligands (18, 22, 25, 41, 42), and inhibits platelet aggregation.
The hemostatic process after a mild injury in vivo only leads 
to limited local activation of platelets and the coagulation system, 
without jeopardizing downstream blood supply (27, 43). Based 
on our results demonstrating the dual role of pFn, we propose a 
novel model to explain the fine balance between maintenance of 
hemostasis and prevention of vessel occlusion. Consistent with a 
previous in vivo study (26), we found that a large amount of fibrin 
is generated close to the injured vessel wall (Figure 7, A and B). 
Therefore, pFn deposited at the base of the hemostatic plug can 
be cross-linked with fibrin. Moreover, the collagen, pFn, and fibrin 
at the base of the thrombi further enhance the ability of activated 
platelets to assemble pFn (44–46). Conversely, the deposited pFn 
further supports extracellular matrix formation, fibrin network 
formation, and platelet aggregation. Unlike the abundance of 
fibrin adjacent to the injured vessel wall, as the thrombus extends 
into the vessel lumen, the generation of fibrin gradually decreases 
(Figure 7, A and B). In the absence of fibrin, the soluble pFn at the 
apical part of thrombi plays a solely inhibitory role, suppressing 
excessive thrombosis and downstream ischemia.
In contrast to a mild injury, when a severe trauma to the ves-
sel occurs (e.g., severed vessels), a large amount of thrombin is 
generated from multiple sites of the injured vessel wall, so that 
even at the top of the growing thrombi, there is likely a sufficient 
amount of thrombin to initiate fibrin formation (Figure 7C). Con-
tinuous fibrin-pFn cross-linking at the top of the growing throm-
bi promotes the formation of an occlusive thrombus (or hemo-
static plug) and helps to stop blood loss efficiently. Therefore, 
pFn appears to be a sensor for the degree of vascular injury and 
modulates the magnitude of the hemostatic response depending 
on the severity of injury.
Maintenance of such a pFn-mediated hemostatic balance may 
be crucial for the treatment of thrombotic and hemorrhagic dis-
eases. First, the current anticoagulant and thrombolytic therapies 
are associated with a high incidence of life-threatening bleeding 
complications, which approaches 10% in patients receiving high-
dose anticoagulants (47). Therefore, it will be important to study 
whether intravenous pFn transfusion could simultaneously main-
tain hemostasis and prevent vessel occlusion in patients with heart 
attack and stroke. Second, there is considerable variation of pFn 
concentration in the human population (20). Notably, congenital 
low pFn (about 50% of normal pFn level) has been reported in a 
family (48). Although these variations in pFn level do not cause 
an overt bleeding phenotype under normal conditions, it may be 
of importance to study whether low pFn level is associated with 
excessive hemorrhage after trauma and surgery. It will also be 
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time in the control group (which could stop bleeding) was calculated 
for the determination of statistical significance.
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sodium citrate (1:9, vol/vol). pFn was isolated from FG–/– mice using 
gelatin-sepharose chromatography. The purity of pFn was evaluated 
by SDS-PAGE analysis. The presence of contaminating Fg was detect-
ed by Western blotting using a rabbit anti-human Fg antibody that also 
detected mouse Fg (American Diagnostica).
Intravital microscopy. The laser-induced cremaster arterial throm-
bosis model was performed as previously described (25, 26, 53, 54). 
Alexa Fluor 488–labeled pFn (5 μg) and DyLight 649 anti-GPIb anti-
bodies (1 μg per 1 g body weight) were injected through the jugular vein 
cannula prior to injury. For detection of fibrin formation, an Alexa Fluor 
488–labeled mouse anti-human fibrin IIβ chain antibody (2 μg per g 
body weight, Accurate Chemical) was injected prior to laser injury. Mul-
tiple independent injuries were induced on cremaster arterioles using 
an Olympus BX51W1 microscope equipped with a pulsed nitrogen dye 
laser. The dynamic deposition of pFn onto the injured vessel wall and 
the formation of the hemostatic plug were captured and analyzed using 
Slidebook software (Intelligent Imaging Innovations).
Confocal microscopy. FeCl3-induced mesenteric arterial thrombo-
sis was produced as previously described (18, 55, 56). After initiation 
of FeCl3 injury, pFn deposition and thrombus formation were record-
ed using a Zeiss LSM 700 confocal laser scanning microscope (Zeiss). 
pFn (5 μg, i.v.) was labeled with Alexa Fluor 647 fluorescent dye, and 
platelets were labeled with Dylight 488 anti-GPIb antibodies (1 μg per 
1 g body weight). The confocal data were analyzed using ZEN 2010 
software (Zeiss), and 3D reconstruction of the images was produced 
by Imaris x64 (Bitplane). The same microscopy and software settings 
were applied in all experiments.
TEG. Blood obtained from the inferior vena cava of mice using 
a 25-gauge needle was immediately mixed with 3.2% sodium citrate 
at a 9:1 ratio. Whole blood and PPP were tested in a TEG 5000 
Analyzer (Hemoscope).
pFn-fibrin network formation in vitro. pFn-fibrin network forma-
tion in vitro was evaluated as previously described (57). For experi-
ments with human plasma, human PPP was added to the gelatin col-
umn. The column pass-through contained minimal amounts of pFn, 
as determined by Western blot analysis. pFn-depleted human PPP was 
used to assess human pFn-fibrin network formation in vitro.
Statistics. Data are presented as mean ± SEM. Statistical signifi-
cance was assessed by the Student’s unpaired (2-tailed) t test or the 
χ2 test with Yates’ correction. P < 0.05 was considered statistically sig-
nificant. For statistical analysis of anticoagulant-treated mice (all of 
which could not stop bleeding), 95% confidence interval of bleeding 
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